Pfizer (NYSE:PFE) came back with another sweetened deal -- this time for 53.50 pounds (or about $119 billion) -- and was yet again rejected by AstraZeneca (NYSE:AZN). This rejection came despite the deal's increase (from a little over $100 billion last time around) and a shift in the deal's mechanics to more cash -- representing 45% of the deal's value compared to the older bid's 33%. AstraZeneca's management said that the company was worth still more money -- about 58.50 pounds per share.
AstraZeneca Chairman Leif Johansson noted that "If Pfizer now says this is the final offer I have to believe what they say."
What if this is the final offer?
In this video from Monday's Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson and discuss the deal and a day that all Pfizer and AstraZeneca investors should circle: May 26th.
Even if Astra bounces back from its 12% loss today, it may have serious trouble competing with this top stock
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.